VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS | ||
| Al-Azhar Journal of Pharmaceutical Sciences | ||
| Volume 68, Issue 2, September 2023, Pages 111-129 PDF (578.41 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ajps.2023.332170 | ||
| Authors | ||
| Helmy Sakr* 1; Islam Otify2; Rezk R Ayyad2; Alaa Elwan2 | ||
| 1Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt | ||
| 2Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt | ||
| Abstract | ||
| Inhibitors of vascular endothelial growth factor receptor -2 (VEGFR-2) are crucial biological targets for the development of novel anticancer medications. Quinazoline also plays an important role as one of the building elements of numerous anticancer drugs. Thus, a review of the literature on VEGFR-2 inhibitors and Quinazoline-based anticancer medicines has been completed. We introduced VEGFR-2 inhibitors now undergoing clinical evaluation, such as Gefitinib, Erlotinib, Vandetanib, Afatinib, Lenvatinib, Cabozantinib, Sorafenib and Regorafenib in our survey. Additionally, VEGFR-2 inhibitors that are under development were introduced. | ||
| Keywords | ||
| Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors; Quinazoline; Anti-cancer agents | ||
|
Supplementary Files
|
||
|
Statistics Article View: 278 PDF Download: 548 |
||
